OctoPlus appoints Jan Hendrik Egberts as CEO
(Thomson Reuters ONE) -
OctoPlus N.V. ("OctoPlus" or the "Company") (Euronext: OCTO), the drug delivery
company, is pleased to announce that its Board of Supervisory Directors has
hired Jan Hendrik Egberts, M.D. and nominated him for appointment as Chief
Executive Officer at the Annual General Meeting of Shareholders in the spring of
2011. He will replace OctoPlus' current CEO Simon Sturge, who will leave the
Company as per 1 January 2011 to lead a large division in a top-15
pharmaceutical company. Dr. Egberts will immediately start working together with
Mr. Sturge until the end of this year to ensure a smooth transition.
"The Board of Supervisory Directors is proud to have recruited Jan Hendrik
Egberts as CEO. He is a highly experienced and skilled professional and we look
forward to welcoming him to the executive team. We are sorry to see Simon go but
we understand his decision to act on a unique job opportunity," says Hans
Stellingsma, Chairman of the Board of Supervisory Directors of OctoPlus. "The
Board nominates Dr. Egberts based on his successful track record in general
management, investment management and business development, which he obtained at
leading innovative and publicly listed companies. We sincerely thank Simon
Sturge for the achievements OctoPlus has made under his leadership."
Proposed CEO Jan Hendrik Egberts, M.D. brings over 20 years of experience in the
pharmaceutical sector to OctoPlus. He graduated from Erasmus University Medical
School in the Netherlands and he pursued the clinical part of his training at
Harvard Medical School. He obtained his MBA from Stanford and started his
business career in clinical research at Organon Teknika in Belgium. He worked
for four years as a strategic consultant to life sciences companies at McKinsey
& Company, and from 1994 onwards held business development and general
management positions of increasing responsibility in the USA at Merck, Johnson &
Johnson and Mölnlycke Health Care. He became CEO of Novadel Pharmaceuticals,
Inc. in 2005. Subsequently, Dr. Egberts has served as Senior Advisor in
healthcare investments to private equity firm 3i Group and has also gained
experience in non-executive positions.
Jan Hendrik Egberts comments: "OctoPlus is making huge progress in
commercialising its controlled release technology. I intend to further build the
value of the Company's portfolio of formulation and manufacturing collaborations
and its drug delivery programs. I am very excited to be part of OctoPlus'
future."
For further information, please contact:
Rianne Roukema, Corporate Communications: telephone number +31 (71) 524 1071, or
send an e-mail to Investor Relations at IR(at)octoplus.nl.
About OctoPlus
OctoPlus is a drug delivery company committed to the creation of improved
pharmaceutical products that are based on OctoPlus' proprietary drug delivery
technologies and have fewer side effects, improved patient convenience and a
better efficacy/safety balance than existing therapies. OctoPlus focuses on the
development of long-acting, controlled release versions of known protein
therapeutics, other drugs, and vaccines on behalf of its clients.
The clinically most advanced product incorporating our technology is Biolex
Therapeutics' lead product Locteron(®), a controlled release formulation of
interferon alpha for the treatment of chronic hepatitis C. OctoPlus licensed
Locteron exclusively to Biolex in October 2008. Locteron is being manufactured
for Biolex by OctoPlus and is currently in Phase IIb clinical studies.
In addition, OctoPlus is a leading European provider of advanced drug
formulation and clinical scale manufacturing services to the pharmaceutical and
biotechnology industries, with a focus on difficult-to-formulate active
pharmaceutical ingredients.
OctoPlus is listed on Euronext Amsterdam by NYSE Euronext under the symbol OCTO.
For more information about OctoPlus, please visit our website www.octoplus.nl.
This document may contain certain forward-looking statements relating to the
business, financial performance and results of OctoPlus and the industry in
which it operates. These statements are based on OctoPlus' current plans,
estimates and projections, as well as its expectations of external conditions
and events. In particular the words "expect", "anticipate", "predict",
"estimate", "project", "plan", "may", "should", "would", "will", "intend",
"believe" and similar expressions are intended to identify forward-looking
statements. We caution investors that a number of important factors, and the
inherent risks and uncertainties that such statements involve, could cause
actual results or outcomes to differ materially from those expressed in any
forward-looking statements. In the event of any inconsistency between an English
version and a Dutch version of this document, the English version will prevail
over the Dutch version.
[HUG#1458780]
Click here for the press release in PDF:
http://hugin.info/137076/R/1458780/398284.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: OctoPlus N.V. via Thomson Reuters ONE
Unternehmensinformation / Kurzprofil:
Datum: 04.11.2010 - 07:31 Uhr
Sprache: Deutsch
News-ID 48400
Anzahl Zeichen: 6248
contact information:
Town:
Leiden
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 182 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"OctoPlus appoints Jan Hendrik Egberts as CEO"
steht unter der journalistisch-redaktionellen Verantwortung von
OctoPlus N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
